<?xml version="1.0" encoding="UTF-8"?>
<p id="p0200">The HIV-1 virus, lead representative of the lentivirus subfamily, is still one of the most serious public health challenges. Since its discovery in the early 1980s, successful and significant efforts have been reached in terms of preventions and treatment: to date, almost 38 million people worldwide are affected by the virus, more than half of which are receiving antiretroviral therapy (ART), a combination of three or more antiretroviral drugs that reduces virus production and correlated disease progression (
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/gho/hiv/en/" id="ir0015" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/gho/hiv/en/</ext-link>, accessed Jan 23, 2020). Nevertheless, there is still no cure to eradicate the virus from the host, and HIV-related deaths continue to impact society and economy: consequently, identification of alternative and effective antiviral targets is urged.
</p>
